SCFA concentrations and dysbiosis in the dog with chronic enteropathy

U.S. study evaluated the effects of intestinal inflammation on fecal concentrations of short-chain fatty acids and gut microbiota structure. Goal: to identify new therapeutic targets

Published on
, bySilvano Marini

It is believed that in the interaction between the host and the gut microbiota a crucial role is played by the products of bacterial metabolism. Short-chain fatty acids (SCFAs), particularly acetate, propionate and butyrate, deserve special attention in this context.

They are the main end products of bacterial fermentation of nondigestible dietary fiber and involve a number of benefits, ranging from immunomodulatory action to antidiarrheal effect and promotion of gastrointestinal motility.

In humans, fecal concentrations of SCFA have been found to be reduced in patients with gastrointestinal disease, with a corresponding increase in the inflammatory state that characterizes these forms.

On the dog with chronic enteropathy, however, data are scarce, as most studies have mainly examined the effects of nutritional interventions on SCFA concentrations in healthy animals. A study conducted at Texas A&M University and published in the Journal of Veterinary Internal Medicine therefore evaluated fecal SCFA concentrations in a group of healthy dogs and in a group of dogs with chronic enteropathy, analyzing the correlations between this finding and the gut microbiota set-up.

The characteristics of the dogs enrolled in the study

The study involved 73 dogs (mean age 4.5 years) with clinical signs of chronic enteropathy of varying degrees and 49 healthy dogs as controls (mean age 6.1 years), belonging to different breeds but comparable in gender and weight. In terms of diet, dogs with enteropathy had lower protein intakes, but both groups had similar intakes of fiber, which is the dietary substrate for bacterial production of SCFA. Among the dogs with enteropathy, 18 were receiving antibiotic therapy, 9 were receiving immunosuppressive drugs, and 5 were following both treatments.

SCFA concentrations and the microbiome setup.

Analyses showed that total SCFA concentrations in feces are significantly reduced in dogs with enteropathy, with acetate and propionate showing a marked reduction. Fecal concentrations of SCFA are not affected by weight, type of enteropathy or its extent, nor by the characteristics of the associated diarrhea. Nor are they affected by the administration of antibiotics or anti-inflammatories.

Regarding the microbiome, the analysis conducted by quantitative PCR identified the following. 11 phyla and 210 genera in total, with the alpha- and beta-diversity that were lower in dogs with enteropathy, in which they appeared reduced Bacteroidetes, Blautia spp., Faecalibacterium spp, Fusobacterium spp., Turicibacter and C. hiranonis, as opposed to Bifidobacterium spp, Lactobacillus spp, Streptococcus spp and E. coli. Drug treatments do not seem to have significantly affected bacterial abundance, but the index of dysbiosis was significantly higher in the group with enteropathy.

For the relationship between fecal concentrations of SCFAs and the abundance of particular bacterial strains, the study revealed a series of 12 associations of propionate and butyrate with the abundance of specific bacterial strains, but none concerning acetate.

How to take advantage of the protective action of SCFAs

Thus, the study confirms that in dogs, enteropathy reduces the concentrations of SCFAs–particularly butyrate and propionate–and that this is accompanied by significant changes in the arrangement of the fecal microbiota, with increased index of dysbiosis.

The goal now is to test how, if, and how much the concentrations of SCFAs can be modified to take full advantage of their protective action in the gut and thus restore a more appropriate immune response.

Source

Minamoto Y, Minamoto T, Isaiah A, et al. Fecal short-chain fatty acid concentrations and dysbiosis in dogs with chronic enteropathy. J Vet Intern Med. 2019;33(4):1608-1618. doi:10.1111/jvim.15520

Explore the latest content
06_02_2024_Probiotici per cani e gatti a che punto siamo
Probiotics for dogs and cats: where do we stand?
02_02_2024_Enteropatia cronica nei cani effetti di simbiotico e IgY sul microbiota intestinale
Chronic enteropathy in dogs: effects of symbiotic and IgY on gut microbiota
19_01_2024_Sicurezza ed efficacia di Limosilactobacillus reuteri DSM 32264 come additivo per mangimi per gatti
Safety and efficacy of Limosilactobacillus reuteri DSM 32264 as a cat feed additive
See more content on e
06_02_2024_Probiotici per cani e gatti a che punto siamo
Probiotics for dogs and cats: where do we stand?
02_02_2024_Enteropatia cronica nei cani effetti di simbiotico e IgY sul microbiota intestinale
Chronic enteropathy in dogs: effects of symbiotic and IgY on gut microbiota
19_01_2024_Sicurezza ed efficacia di Limosilactobacillus reuteri DSM 32264 come additivo per mangimi per gatti
Safety and efficacy of Limosilactobacillus reuteri DSM 32264 as a cat feed additive
11_01_2024_Caratteristiche probiotiche del Lactobacillus reuteri
Probiotic characteristics of Lactobacillus reuteri
11_01_2024_Rapporto ufficiale EFSA sull’efficacia di Lactobacillus reuteri DSM 32203 (NBF LANES) per cani
Official EFSA report on the efficacy of Lactobacillus reuteri DSM 32203 (NBF LANES) for dogs
11_01_2024_Effetti del Lactobacillus reuteri NBF1 sulla salute del cane sano
Effects of Lactobacillus reuteri NBF1 on the health of the healthy dog
11_01_2024_Effetti dell'integrazione di Lactobacillus reuteri NBF 1 sul Bouledogue francese
Effects of Lactobacillus reuteri NBF 1 supplementation on French Bouledogue
21_07_2023_Cani obesi e cani normopeso ecco come cambia il microbiota
Obese dogs and normal-weight dogs: here's how the microbiota changes